A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Project: Research

Project Details

StatusActive
Effective start/end date26/02/24 → 25/02/29

Clinical Trial Phase

  • Phase I
  • Phase II